重症虚血肢に対する血管新生遺伝子治療

概要

論文の詳細を見る
Critical limb ischemia (CLI) manifesting pain at rest and/or loss of tissue integrity ultimately leads to amputation of a portion of the lower extremities, and prognosis in these patients is generally poor with conventional medical or surgical therapies. Recently, a novel therapeutic strategy using gene transfer of an angiogenic factor such as vascular endothelial growth factor (VEGF) has been stablished, and is reported to cause subsequent angiogenesis and improve clinical ischemia in patients with CLI. Angiopoietin-1 (Ang1) is known to play important roles in vascular formation and maturation ooperatively with VEGF, and may enhance VEGF-induced angiogenesis. Preclinical animal studies indicate that pre-administration of Ang1 followed by VEGF is most beneficial for therapeutic angiogenesis with no significant adverse effect, and encouraged us for clinical study. In this article, we also describe proposed clinical protocol to document the safety and bioactivity of this strategy for CLI patients with no therapeutic option.
札幌医科大学の論文
2004-06-01